Gyre Therapeutics (GYRE) EBT (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly EBT of -$9.2 million for Q1 2026, down 299.29% year-over-year from $4.6 million in Q1 2025, and down 13895.45% quarter-over-quarter from -$66000.0 in Q4 2025.
Gyre Therapeutics (GYRE) EBT (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported EBT for 17 consecutive years, with -$9.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 299.29% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at $564000.0 (down 96.33% YoY), while the FY2025 annual figure was $14.4 million, down 37.82% from the prior year.
- EBT eased to -$9.2 million in Q1 2026 per GYRE's latest filing, from -$66000.0 in the prior quarter.
- Across five years, EBT topped out at $51.6 million in Q2 2022 and bottomed at -$100.3 million in Q4 2023.
- Historically, EBT has averaged -$2.3 million across 5 years, with a median of $3.9 million in 2024.
- On a YoY basis, EBT climbed as much as 329.07% in 2023 and fell as far as 339.82% in 2023.
- Gyre Therapeutics' EBT stood at -$22.8 million in 2022, then sank by 339.82% to -$100.3 million in 2023, then soared by 100.77% to $772000.0 in 2024, then tumbled by 108.55% to -$66000.0 in 2025, then slumped by 13895.45% to -$9.2 million in 2026.
- Business Quant data shows GYRE's EBT at -$9.2 million in Q1 2026, -$66000.0 in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -14.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.43 Mn |
| Mar 31, 2026 | -9.24 Mn |
| Dec 31, 2025 | -66,000.00 |
| Sep 30, 2025 | 7.63 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 4.64 Mn |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 3.93 Mn |
| Jun 30, 2024 | 6.04 Mn |
| Mar 31, 2024 | 12.48 Mn |
| Dec 31, 2023 | -100.28 Mn |
| Sep 30, 2023 | 11.19 Mn |
| Jun 30, 2023 | 5.85 Mn |
| Mar 31, 2023 | 6.27 Mn |
| Dec 31, 2022 | -22.80 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.99 Mn |
| Sep 30, 2021 | -27.71 Mn |